It probably is good for the public interest, and frankly for the manufacturing ecosystem, for the FDA to be directed (and given the authority) to disclose the third party whose “facility-related deficiencies” identified during a Current Good Manufacturing Practices (cGMP) results in a CRL.
A little public shaming would probably help deal with widespread structural deficiencies amongst CDMOs.
Something certainly needs to happen, this is happening way to often.
Investigations of a Dog 